Global Cancer Supportive Care Market 2017-2021
About Cancer Supportive Care
Cancer supportive care drugs are used for the treatment of adverse effects caused due to the cancer treatment such as chemotherapy-induced anemia, CINV, bone metastasis, cancer pain, and others. Various class of drugs are used as cancer supportive care drugs. Some of the major drug class that involves in cancer supportive care are antiemetic drugs, erythropoietin-stimulating agents, granulocyte-stimulating agents, analgesics, and others.
Technavio’s analysts forecast the global cancer supportive care market to grow at a CAGR of 3.38% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global cancer supportive care market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs in cancer supportive care market.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Cancer Supportive Care Market 2017-2021
Technavio recognizes the following companies as the key players in the global cancer supportive care market: Amgen, Helsinn Healthcare, Johnson &Johnson, and Merck.
Other Prominent Vendors in the market are: F. Hoffmann-La Roche, GlaxoSmithKline, Heron Therapeutics, Kyowa Hakko Kirin, Novartis, TESARO, and Teva Pharmaceutical Industries.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is advent of biosimilars in cancer-associated treatment. The growing demand for quality care has led to the increased use of erythropoietin drugs for the treatment of chemotherapy-induced anemia. The majority of countries are under pressure to address this demand without increasing healthcare expenditure.”
According to the report, one driver in the market is large number of side effects associated with the cancer treatment. Progress in cancer treatment has come with several challenges that go beyond a cure. Morbidity and toxicities are among the few of the biggest hurdles faced by cancer patients while going through radiation therapy or chemotherapy. A large number of side effects are associated with the treatment of cancer. These have been a major challenge for the traditional cancer treatment market (radiation and chemotherapy). The main aim of cancer treatment is to get rid of the cancer cells.
Further, the report states that one challenge in the market is rising popularity of targeted therapies for the treatment of cancer in developed countries. The increasing preference of targeted therapies instead of chemotherapy drugs will hinder the growth prospects in the market. As there is an increased need to target-specific molecules that are responsible for the growth of cancer, the vendors are focusing on the development of targeted therapies, which are highly specific than the traditional chemotherapy drugs. Also, as chemotherapy drugs are associated with higher side effects, the researchers are extensively conducting R&D activities to understand the disease etiology better and develop novel treatments.
Amgen, Helsinn Healthcare, Johnson &Johnson, and Merck, F. Hoffmann-La Roche, GlaxoSmithKline, Heron Therapeutics, Kyowa Hakko Kirin, Novartis, TESARO, and Teva Pharmaceutical Industries.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook